Brian M. Shuch, MD

Associate Professor Adjunct

Research Departments & Organizations

Urology: Urologic Oncology Program

Office of Cooperative Research

Research Interests

Adrenal Cortex Neoplasms; Genetics; Neoplastic Syndromes, Hereditary; Urinary Tract; Urologic Neoplasms

Research Summary

1) Molecular characterization of sporadic and hereditary kidney cancer

2) Development of novel therapeutic strategies for Kidney cancer

3) Development of novel biomarkers to avoid overtreatment of small renal masses

4) Integration of molecular diagnostics and Genomics data to patient care

Extensive Research Description

1) Development of a Genitourinary Biorepository- currently we are establishing a GU cancer repository with well anotated clinical information. This will be a major resource for the Yale Cancer Center as any investigator wishing to perform translational research will have access to cancer tissue, urine, and blood samples.

2) Kidney Cancer Genetics Evaluation Program- This clinical program is focus on the identification of new kidney cancer syndromes. All patients are referred through the team for whole genome sequencing. We have a CLIA approved gene panel for kidney cancer. The other genes are for research purposes. Creation of cell lined and having available tissue will allow characterization of potential new germline cancer syndromes.

3) Neoadjuvant RCC trials- We have submitted proposals to treat patients with metastatic disease with novel immunotherapy prior to cytoreductive surgery for clear cell RCC. The primary end point is to see if we can have a much improved systemic response harnessing the primary tumor to interact with the immune system. We have conditional approval from 2 companies to partner with us for the protocol.

4) Active surveillance RCC trial- we are creating a trial aimed at avoiding overtreatment of small tumors. We plan on opening this shortly and will use advanced genomic techniques for tumor characterization.

5) Genomic heterogeneity in Small renal masses- My K08 evaluates the impact of molecular subtype, driver copy number changes, and driver mutations in various regions of kidney cancer. We investigate how this impacts selection of therapy in patients with small renal masses.

Clinical Trials

Conditions Study Title
Prostate Assessing the Clinical Response of Prostate Cancer to a Fermented Soy Extract

Activities

  • “Management of Kidney Cancer in Young Patients” Chicago, United States (2014 - 2014)

    Presentation at the 2014 Kidney Cancer Symposium

  • “Surgery in the Setting of Metastatic Disease” Chicago, United States (2013 - 2013)

    Presentation at the 2013 Kidney Cancer Symposium

  • “Defining Early-Onset Kidney Cancer: Implications for Age-Based Genetic Counseling” Orlando, United States (2013 - 2013)

    Presentation at the 2013 ASCO GU Cancer Symposium

  • “Adrenal Hyperplasia as part of the Hereditary Leiomyomatosis and Renal Cell Cancer Phenotype.” Bethesda, United States (2011 - 2011)

    Presentation at the Society of Urologic Oncology Winter Meeting 2011

  • “Cytoreductive Nephrectomy for Patients with Advanced Kidney Cancer and Sarcomatoid Histology.” Orlando, United States (2009 - 2009)

    Presentation at the 2009 ASCO GU Cancer Symposium

  • “Histologic Evaluation of Metastases in Renal Cell Carcinoma with Sarcomatoid Transformation and its Implications for Systemic Therapy.” Los Angeles, United States (2009 - 2009)

    Presentation at the UCLA Longmire Surgical Society

  • “Brain Metastasis from Renal Cell Carcinoma: Presentation, Recurrence, and Survival.” Los Angeles, United States (2008 - 2008)

    Presentation at the UCLA Longmire Surgical Society

  • “Brain Metastasis from Renal Cell Carcinoma: Presentation, Recurrence, and Survival.” San Francisco, United States (2008 - 2008)

    Presentation at the 2009 ASCO GU Cancer Symposium

Selected Publications

  • Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.

    Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113:2170-5. 2016

  • Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.

    Chen F, Zhang Y, Senbabaoglu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, Muzny D, Kang H, Lee J, Tamboli P, Reuter V, Shelley CS, Kaipparettu BA, Bottaro DP, Godwin AK, Gibbs RA, Getz G, Kucherlapati R, Park PJ, Sander C, Henske EP, Zhou JH, Kwiatkowski DJ, Ho TH, Choueiri TK, Hsieh JJ, Akbani R, Mills GB, Hakimi AA, Wheeler DA, Creighton CJ. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Reports 2016, 14:2476-89. 2016

  • MET Inhibition in Clear Cell Renal Cell Carcinoma.

    Xie Z, Lee YH, Boeke M, Jilaveanu LB, Liu Z, Bottaro DP, Kluger HM, Shuch B. MET Inhibition in Clear Cell Renal Cell Carcinoma. Journal Of Cancer 2016, 7:1205-14. 2016

  • Racial disparities in renal cell carcinoma: a single-payer healthcare experience.

    Mafolasire A, Yao X, Nawaf C, Suarez-Sarmiento A, Chow WH, Zhao W, Corley D, Hofmann JN, Purdue M, Adeniran AJ, Shuch B. Racial disparities in renal cell carcinoma: a single-payer healthcare experience. Cancer Medicine 2016, 5:2101-8. 2016

See list of PubMed publications

Edit this profile